Podcasts Technology Acquired Novo Nordisk (Ozempic)

Novo Nordisk (Ozempic)

Published: Jan. 22, 2024, 1:59 a.m.

Last year Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, overtook LVMH to become Europe\u2019s most valuable company. And the pull for Acquired to finally tackle healthcare (18% of US GDP!) became too strong for us to resist. While we didn\u2019t know much about Novo Nordisk before diving in, our first thought was, \u201cwow, seems like these new diabetes and obesity drugs mean serious trouble for big insulin companies.\u201d

And then\u2026 we realized that Novo Nordisk IS the big insulin company. And in a story befitting of Steve Jobs and Apple, they\u2019d just disrupted themselves with the drug equivalent of an iPhone moment. Once we dug further, we quickly realized this company has it all: an incredible 100+ year history filled with Nobel Prizes, bitter personal rivalries, board room dramas, a generation-defining silicon valley innovation, lone voices persevering against all odds \u2014 and oh yeah, the world\u2019s largest charitable foundation at its helm. Tune in for one incredible story!

Sponsors:

Many thanks to our fantastic Season 14 partners:

More Acquired:

Links:

Carve Outs:

\u200dNote: Acquired hosts and guests may hold assets discussed in this episode. This podcast is not investment advice, and is intended for informational and entertainment purposes only. You should do your own research and make your own independent decisions when considering any financial transactions.